CATEGORY
ICER
- ABPI
- ACE
- ACIS
- Adelaide
- Aetsa
- Agenas
- AHRQ
- AIFA
- AMNOG
- ANVISA
- AOTMiT
- AQuAS
- Behandlingsraadet
- BfArM
- Biocat
- C2H
- CADTH
- CDC
- CDE
- CMS
- COFEPRIS
- CONITEC
- Digemid
- EFPIA
- EMA
- EPF
- Eucope
- EUnetHTA
- EuropaBio
- European Commission
- Euskadi
- FDA
- FOPH
- G-BA
- Gesundheit Österreich
- HAS
- Health Technology Wales
- Healthcare Improvement Scotland
- HHS
- HIQA
- HTAi
- ICER
- IECS
- IETS
- IHE
- IHEA
- INAHTA
- IQWiG
- ISPOR
- KCE
- Medicaid
- Medicines for Europe
- MHRA
- MSP
- NECA
- NHS
- nHTA
- NICE
- NIH
- NIHO
- NIHR
- NIPH
- NSW Health
- NZa
- OHE
- OYS
- PBS
- pCPA
- Pharmac
- PhRMA
- Salute
- SBU
- Schönermark Kielhorn Collegen
- SGK
- TÄ°TCK
- TLV
- WHO
- ZonMw
- Zorginstituut Nederland
ICER to Assess Treatments for Spinal Muscular Atrophy
Barriers to Fair Access in US Drug Coverage
ICER Report Highlights Unsupported Drug Price Increases in 2023
ICER Releases Draft Report on Acute Pain Treatment
Tabelecleucel Shows Promise for Epstein-Barr Virus Cancer Treatment
ICER to Assess Tolebrutinib for Secondary Progressive MS in 2025
ICER Evaluates Cost-Effectiveness of ATTR-CM Treatments
New Screening Method for Early Preeclampsia Shows Promising Results in Catalonia
Medicare Set to Include COPD Drugs in Next Round of Price Negotiations, ICER Prepares Evaluation
ICER to Assess New Treatment for Retinitis Pigmentosa
ICER Draft Report Evaluates Treatment for EBV+ PTLD
August 2024 Milestones for Institute for Clinical and Economic Review
ICER Publishes Evidence Report on Transthyretin Amyloid Cardiomyopathy Treatments
ICER Report Highlights Pricing Concerns for Imetelstat in Myelodysplastic Syndrome Treatment
July 2024 Milestones for Institute for Clinical and Economic Review